Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur

J Infect Chemother. 2016 Dec;22(12):826-829. doi: 10.1016/j.jiac.2016.07.009. Epub 2016 Aug 12.

Abstract

When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis. In case of persistent clinical symptoms despite discontinuation of chemotherapy, cytomegalovirus colitis should be considered in the differential diagnosis of chemotherapy-induced enterocolitis. We herein report the case of a patient who underwent surgery for lung adenocarcinoma followed by postoperative adjuvant chemotherapy with uracil-tegafur and was diagnosed as having cytomegalovirus colitis during the therapy. In the course of chemotherapy, cytomegalovirus colitis occasionally occurs even though the patient does not experience severe myelosuppression; thus, it is necessary that we recognize its potential occurrence.

Keywords: 5-Fluorouracil-induced enterocolitis; Adverse effect; Chemotherapy; Cytomegalovirus colitis; Lymphopenia; Uracil-tegafur.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma of Lung
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant / methods
  • Colitis / diagnosis*
  • Colitis / virology*
  • Cytomegalovirus / isolation & purification*
  • Cytomegalovirus Infections / diagnosis*
  • Cytomegalovirus Infections / virology
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Lung Neoplasms / drug therapy*
  • Postoperative Care
  • Tegafur / administration & dosage

Substances

  • Tegafur
  • Fluorouracil